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SUMMARY 
The premenstrual syndrome (PMS) has been proposed to result from excessive exposure to 
and/or withdrawal of brain opioid activity during the luteal phase. Because hypothalamic opioids 
are believed to modulate GnRH secretion, in part under the influence of ovarian steroids, we per- 
formed longitudinal studies of gonadotropin and ovarian steroid secretion across ovulatory, symp- 
tomatic cycles of 17 PMS patients and 8 normal volunteers. Pulsatile LH secretion was measured 
every 10 min for 8 hr at times when central opioid activity was expected to be low (early follicular 
phase), high (mid-luteal phase; ML), and declining (late luteal phase). In both subject groups, a 
cycle-phase effect was observed for LH pulse frequency (p =<0.001) and amplitude (p =0.002), and 
for the transverse mean concentrations of LH (p =0.05), FSH (p <= 0.001), estradiol (E2) 
(p=<0.001) and progesterone (P) (p =<0.001). ML P secretion in PMS patients was pulsatile, and 
mean concentrations (over 30-60 min) were similar to those of normal controls. The changes in 
pulsatile LH secretion across the cycle were not different in the PMS patients compared to the 
normal women, though mean FSH in the ML phase was higher in the PMS group (p =<0.05). The 
similar changes in luteal LH pulse frequency fail to provide evidence that GnRH secretion is 
impaired, thus challenging the view that the neuroregulation of the menstrual cycle in women with 
PMS is markedly altered. 
INTRODUCTION 
THE MECHANISMS INVOLVED in producing the complex of symptoms collectively termed the pre- 
menstrual syndrome (PMS) are unknown. The failure to identify gross aberrations in plasma 
concentrations of the reproductive hormones has led investigators to search for a common link 
between the dynamic neuroendocrine secretory events that characterize the menstrual cycle and 
central mechanisms regulating behavior and mood states. It has been proposed that premen- 
strual symptoms occur in response to the cyclic rise and fall in hypothalamic opioid activity 
believed to modulate the pulsatile release of gonadotropin-releasing hormone (GnRH) and, in 
turn, luteinizing hormone (LH), as a result of the characteristic changes in the ovarian produc- 
tion of  estrogen and progesterone (P) (Halbreich & Endicott, 1981; Reid & Yen, 1981). 
Advocates propose that the withdrawal of high opioid activity prior to menses disinhibits 
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opioid-sensitive neurons, resulting in such dysphoric symptoms as irritability, insomnia, food 
cravings, anxiety, and pain sensitivity (Chuong et  al . ,  1988; Facchinetti et  al . ,  1988; 1990). 
LH pulse frequency in the mid-luteal (ML) phase has been reported to be faster in PMS patients, 
despite similar concentrations of  P compared to normal volunteers (Facchinetti et al., 1990). 
This finding, as well as earlier evidence that LH responsiveness  to the opiate antagonist ,  
naloxone, was blunted in PMS patients (Facchinetti et  al . ,  1988), prompted these investigators 
to propose that PMS was a central disorder, due to a hypothalamic impairment of  the opioid 
inhibition normally present at this time in the cycle. Differences in LH pulse frequency and 
amplitude between the patient and control groups in the later study (Facchinetti et  al . ,  1990) 
were small, however, and secretory characteristics were within the normal range of  variability 
previously reported for normal, asymptomatic women (Reame et  al . ,  1984). In addition, these 
investigators noted that the presence of  secondary psychiatric disorders in some of  the PMS 
subjects may have confounded their results. 
Given  the recognized  role o f  endogenous  opioids  in media t ing  the luteal s lowing of  
GnRH/LH pulsatile secretion (Quigley & Yen, 1980; van Vugt et  al . ,  1984), and to further char- 
acterize the neuroreproductive axis in PMS, we conducted a longitudinal assessment of  pulsatile 
gonadotropin and ovarian steroid secretion in women with PMS at times in the menstrual cycle 
previously shown to be differentially influenced by central opioid activity (Quigley & Yen, 
1980; Wardlaw e t  al . ,  1982). 
SUBJECTS AND METHODS 
Subjects 
Twenty women between the ages of 26 and 39 yr (mean + SEM = 32.9 + 4 yr) were recruited from a pool of 
172 gynecologic patients diagnosed with PMS as defined by the National Institute of Mental Health guidelines 
(Blume, 1983). Subjects were referred by their clinician after symptom assessment but prior to the initiation of 
therapy. The diagnosis of PMS was based on prospective confirmation of the presence of luteal phase emo- 
tional and physical symptoms which resolved before the end of menses and occurred in at least two subsequent 
cycles. The symptom rating scales used by the referring physicians included the Self Rating Scale for 
Premenstrual Tension Syndrome (Steiner et al., 1980), the Prospective Record of the Impact and Severity of 
Menstrual Symptomatology (PRISM) calendar (Reid, 1985), and a visual linear analogue scale (Casper & 
Powell, 1986). 
Selection criteria included a history of regular menses, normal body weight (+15% ideal body weight 
[IBW]) and 6 mo or more of cyclic distress resulting in significant disruption of personal or professional func- 
tioning. The mean duration of PMS symptoms was 5.2+0.4 yr (range 3-9  yr). All subjects were free of 
demonstrable medical illness and had not been taking medications, including oral contraceptives, during the 
previous 6 mo. There was no evidence of psychiatric dysfunction as measured by the SCL-90 Questionnaire 
(Derogatis et al., 1976), the Center for Epidemiologic Studies Depression Scale (Radloff, 1977), or psychiatric 
interview conducted during the follicular phase of the cycle. There was no hirsutism or clinical evidence of 
thyroid disease on physical examination, and plasma prolactin, testosterone, dihydroepiandrosterone sulphate, 
and beta human chorionic gonadotropin were normal at the time of study. 
Protocol 
The studies were approved by the Institutional Review Board and were performed in the Clinical Research 
Center of the University of Michigan Hospital after written informed consent had been obtained. 
LH pulsatility was assessed longitudinally at three time points in the menstrual cycle which have been previ- 
ously well-characterized in normal women, and when endogenous opioid activity is presumed to be minimal 
(early follicular phase; EF), maximal ML phase and diminished (late luteal phase; LL). Studies were conducted 
on days 5-6  after menses onset (EF), days 5-9  post-LH surge (ML), and days 11-15 post-LH surge (LL). In all 
cases, the ML and LL studies were at least 5 days apart. During each 8-hr study (0900h-  
1700h), blood samples were obtained through an indwelling intravenous forearm catheter every 10 min for 
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measurement of LH, every 60 min for FSH, every 30 min for P in the ML and 60 min in the LL, and every 2 hr 
for estradiol (F_~.). The timing of the LH surge was estimated by the increase in urinary LH determined with a 
home, enzyme-linked immunosorbent assay kit (First Response TM, Tambrands, Lake Success, NY). Blood also 
was obtained for determination of F_~ and P every other day between the ML and LL study days. 
Symptom Assessment 
To confirm menstrual symptom characteristics during the study cycle, subjects rated themselves on the inci- 
dence and severity of 40 symptoms commonly associated with menstrual cycle distress using a check list devel- 
oped by Woods (1987), based on the work of Moos (1968), Haskett et al. (1980), and Halbreich et al. (1982). 
Beginning 2 wk prior to the onset of the study cycle, women rated the items on a scale of 0 (not present) to 4 
(extreme) at the end of each day. The 40 menstrual-related items were embedded alphabetically within a larger 
list of 57 negative and positive symptoms (e.g., blurred vision, general well-being). After data collection, the 
daily diaries were synchronized with menstrual cycle days. The three highest daily symptom scores of the post- 
menstrual week (days 4 through 10 after menses onset) and the subsequent premenstrual week (days 7 through 
1 premenses) were used to compute a menstrual phase mean score (Woods, 1987). 
Control Studies in Normal Volunteers 
Eight normal volunteers prospectively monitored body symptoms across a menstrual cycle during which 
blood-sampling studies were performed in the EF and ML. In four subjects, a third study was conducted in the 
LL. Criteria for subject selection included: 21-39 yr of age, regular cycles of 25-32 days, normal body 
weight (+ 15% IBW), postpartum and nonlactating for at least 6 mo, no medication use including oral contra- 
ceptives for the previous 6 mo, no history of medical treatment for endocrine or gynecologic disease including 
debilitating premenstrual/menstrual complaints, and normal findings on physical examination. 
Assays 
Plasma LH and FSH were measured by (RIA) methods previously reported (Midgley, 1966; 1967). Plasma 
F a (assay sensitivity: 5 pg/ml, 18 pmol/l) and P (assay sensitivity: 0.2 ng/ml, 0.64 nmol/1) were measured with 
RIA kits (Diagnostic Products, Los Angeles, CA; Radioassay Systems Laboratories, Carson, CA). Gonadotro- 
pin concentrations are reported as IU/1 of the second IRP human menopausal gonadotropin after conversion 
from LER 907, which was used as the assay standard. For the LH and FSH assays, the assay sensitivities were 
1.0 and 1.4 IU/I, respectively, and the interassay coefficient of variation (CV) was 11%. For LH and FSH, the 
intraassay CV was inversely proportional to the measured amount, averaging 20%, 9.5% and 6.6% for concen- 
trations of 2.5, 7.5 and 15 IU/1, respectively. For analysis, values below assay sensitivity were assigned a value 
of the assay sensitivity. 
LH Pulse Analysis 
The number of LH pulses occurring in each 8-hr sampling period was determined as previously described 
(Reame et al., 1984; Hale et al., 1988). A minimal detectable increment (MDI) was determined for each 8-hr 
sampling period. The MDI was calculated as the product of the mean LH concentration and three times the 
intraassay coefficient of variation (CV) of replicate samples for each sampling period (MDI = mean LH × CV x 
3). If the calculated MDI was less than the assay sensitivity for that period, the value of the assay sensitivity 
was used. An LH pulse was defined as an increase from nadir to peak greater than or equal to the MDI, occur- 
ring within 40 min. The LH pulse amplitude was calculated as the difference between the peak value and the 
preceding nadir value. Only those pulses with amplitudes exceeding the mean assay sensitivity (1.0 IU/1) were 
accepted. The maximum false positive rate was less than 1-2 pulses/100 comparisons. Missing values com- 
prised less than 0.5% of the total samples and were left blank. This method of pulse analysis has been 
compared in previous studies of normal women to the computerized peak detection program, Detect, version 
4.8 (Oerter et al., 1986), and shown to provide similar estimates of pulse frequency (Nippoldt et al., 1989). 
Statistical Analysis 
Data are presented as means +SEM. Hormone values are expressed as IU/1 for LH and FSH, nmol/1 for P, 
and pmol/l for E 2 (1 ng= 3.18 nmol; 1 pg = 3.6 pmol). The distribution of hormone values was assessed for 
normality. In some cases, a log transformation was needed due to skewed distribution; however, transformation 
did not change any of the results, and the transformed data axe not reported. Differences in mean hormone 
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secretion characteristics across the three cycle phases in the patient and control groups were determined by 
analysis of variance and multiple comparison procedures (Fisher's least significant difference or Sheffe) if the 
overall F ratio was significant (p =< 0.05). 
RESULTS 
Menstrual Cycle Characteristics 
Study cycles from all subjects were judged to be ovulatory as evidenced by plasma P values 
of > 15 nmol/1 (5 ng/ml) on at least two occasions in the ML phase. In three subjects in the 
PMS group, peak plasma P levels were not observed until 11 to 14 days after the estimated LH 
surge, and cycle lengths were 22, 37 and 40 days. Post-study cycles were 26, 28 and 25 days 
in length, respectively. Because these observations suggested atypical ovulatory cycles, the 
data from these individuals were excluded from analysis, resulting in a final sample size of 17 
in the PMS group. None of the normal volunteers experienced an atypical cycle during the 
study, although it has been our experience over the last 10 yr that abnormal cycles occur in 
approximately 10% of subjects who undergo these intensive studies. 
Symptom Characteristics During Study 
In both the postmenstrual and the premenstrual weeks of the study cycle, the volunteer 
group demonstrated a lower mean symptom score (p = 0.001, ANOVA) than the patient group. 
Mean age and cycle length were similar (Table I). Since underlying psychiatric disorders had 
been ruled out during the diagnostic evaluation, the higher "baseline" scores of the postmen- 
strual week more likely reflected the chronic nature and severity of the menstrual health 
problem. Little is known about how PMS symptom patterns change over time, especially in 
women who fail to benefit from standard treatment approaches. It has been proposed that for 
women suffering from severe, long-term premenstrual symptoms, the "symptom-free" interval 
associated with the follicular phase is compromised by feelings of guilt and depression for 
neglect of family and professional responsibilities (Reid, 1985). 
The PMS group showed an almost three-fold increase in mean symptom scores in the subse- 
quent premenstrual week (57.9+ 6) compared to postmenstrual values (19.8 + 4.0; p =0.001, 
ANOVA). The scores of most PMS subjects greatly exceeded the minimum 30% increase (% 
mean increase+SEM=525+ 181%; range=36% to 2250%) required to meet the definition for 
PMS adopted by the National Institutes of Mental Health PMS Research Workshop Workgroup 
(Blume, 1983). 
TABLE I. CLINICAL CHARACTERISTICS AND MENSTRUAL SYMPTOM SCORES (MEAN-----SEM) 
AT THE TIME OF STUDY FOR PMS PATIENTS AND NORMAL VOLUNTEERS (NV) 
Age Study Cycle Symptom Score 
Group n (yr) Length (days) Post-Menses Pre-Menses 
PMS 17 32.3+ 0.8 27.7+ 0.7 19.8+ 4.0 57.9+ 6.0 
NV 8 32.0+ 0.2 27.1 + 1.0 7.5+ 3.0 8.9+ 3.0 
tPost-  vs. Pre- (PMS}: p=O.O01; PMS vs. NV: p=O.O01. 
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Gonadotropin and Ovarian Steroid Secretion in PMS Patients 
By ANOVA, a significant luteal phase change occurred in mean LH concentration, LH pulse 
frequency, LH pulse amplitude, mean FSH, and mean levels of  F_. 2 and P (Table ID. LH pulse 
frequency slowed from an EF frequency of 7.5+ 0.6 pulses/8 hr to 4.0+0.3 pulses/8 hr in the 
ML, and pulse amplitude increased from 2.2+ 0.2 IU/1 (EF) to 4 .6+0.7 IU/1 (ML). Mean FSH 
was lower in the ML when ovarian steroids were elevated. Figure 1 presents serial measures of 
plasma gonadotropins and ovarian steroids in two subjects with PMS showing representative 
changes in pulsatile LH secretion between the follicular and luteal studies. 
During the ML studies, plasma P was measured every 30 min and assessed for pulsatile 
secretion. By criteria previously used in normal women (a secretory pulse was defined as an 
increase of five times the SEM of the mean within 120 min of the previous nadir [Healy et al., 
1984]), secretory fluctuations of  12.7+2.0 nmol/1 (4.0+ 0.7 ng/ml)  amplitude occurred at a 
mean frequency of 2.4 + 0.4 pulses/8 hr. Figure 2 shows ML P secretion in three subjects with 
varying severity of PMS symptoms. During the ML studies, plasma P was close to the group 
mean level (30.9+ 4.0 nmol/1; 9.5+1 ng/ml) in PMS subjects with both high (Subject 5) and 
low (Subject 6) symptom severity scores. In Subject 2, low symptom severity scores were 
associated with plasma P levels in the high-normal range, but LH pulse frequency was not 
excessively slowed in this individual (5 pulses/8 hr). Overall, there was no significant correla- 
tion between MLP concentrations and premenstrual symptom scores. 
Comparison of Data in PMS Subjects and Normal Volunteers 
Plasma ovarian steroids were not statistically different between groups on the three study 
days, although in the LL, a lower mean value for both E 2 and P in the normal volunteers was 
apparent. The four normal volunteers were all evaluated on the day prior to menses, resulting 
TABLE II. PLASMA GONADOTROPIN AND OVARIAN STEROIDS IN PMS SUBJECTS 
AND NORMAL VOLUNTEERS AT SIMILAR PHASES OF THE MENSTRUAL CYCLE (MEAN'{- SEM) 
Group 
Cycle Phase (Days + LH Surge) 
EF (-10 to -7) ML (+ 5 to +9) LL (+11 to +15) 
Mean LH PMS 6.5 + 0.6* 5.1 + 0.6 5.5+ 0.5 
(IU/D NV 5.8 + 0.7** 3.8+ 0.3 5.1 + 0.5 
LH pulse frequency PMS 7.5 + 0.6** 4.0+ 0.3 5.2+ 0.5 
(pulses/8 hr) NV 5.9 + 1.0"* 2.8+ 0.5 6.0+ 0.7 
LH pulse amplitude PMS 2.2 + 0.2*** 4.6+ 0.7 3.1 + 0.3 
(IU/1) NV 2.2 + 0.2*** 4.0± 1.1 3.1 + 0.5 
Mean P PMS 0.6 + 0"* 30.9± 4.0 8+ 2 
(nmol/1) NV 0.6 ± 0"* 27.7± 3.0 1.3± 0.3 
Mean E 2 PMS 166 ± 15"* 290± 26 184± 26 
(pmol/1) NV 103 ± 22** 334± 40 73± 11 
Mean FSH PMS 6.7 + 0.6** 4.6± 0.6t 5.4± 0.6 
(IU/1) NV 5.1 ± 0.5** 1.7± 0.3 4.1 + 0.7 
EF = early follicular, ML = mid-luteal, LL = late luteal. 
PMS = premcnstrual syndrome patients (n= 17); NV = normal volunteers (n=8 at EF and ML, n=4 at LL) 
*EFvs. ML, p=0.05 **EFvs. ML, p=<0.001 ***EFvs. ML, p-0.002 tpMSvs. NV, p=<0.05 
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in lower values compared to the PMS group, in whom LL studies were performed on average 2 
days prior to menses. Single measures of E 2 and P taken between the ML and LL studies 
(days 9 and 11 post-LH surge) revealed no difference in the rate of decline in corpus luteum 
function for the two groups. 
Mean plasma FSH was different in the PMS and control groups (p = 0.002; ANOVA), in that 
mean FSH was higher in the PMS patients in the ML studies (p =<0.05, Fisher's multiple com- 
parison). No significant differences in pulsatile LH secretory characteristics were found 
between PMS patients and normal volunteers across the three study days. 
DISCUSSION 
We studied changes in pulsatile LH secretion in women with PMS to detect peripheral 
evidence of alterations in the transient increase and withdrawal of endogenous opioid action on 
GnRH secretion during ovulatory, symptomatic cycles. We chose three different "windows" in 
the menstrual cycle which have been characterized previously in relation to ovarian steroids, 
gonadotropin secretion, menstrual symptomatology, and presumed opioid activity. The current 
view of the hormonal interrelationships in the normal luteal phase is that P in the presence of E 2 
acts on the hypothalamus to transiently increase opioid activity, thus inhibiting the frequency of 
pulsatile GnRH secretion and in turn the pulsatile release of LH (Yen et  al., 1972; Backstrom et 
al., 1982; Filicori et  al., 1984; Soules et al., 1984). With the fall in E 2 and P secretion from the 
aging corpus luteum, opioid exposure is withdrawn, allowing GnRH pulsatile secretion to 
increase in the days preceding menses (Marshall & Kelch, 1986). Thus, assessment of LH 
pulse frequency in women has been used to infer changes in GnRH secretion and may allow a 
gross estimation of hypothalamic opioid influence when performed in the presence of a well- 
defined ovarian steroid milieu. 
A more direct measure of hypothalamic opioid activity is LH responsiveness to naloxone 
infusion, which was not assessed in the present study. We chose to characterize the phasic 
changes in endogenous pulsatile LH secretion without the potential effects of an agent known to 
influence LH pulse characteristics and possibly PMS symptoms. Therapeutic effects of naltrex- 
one, the orally active opiate antagonist, have been observed in a placebo-controlled, double- 
blinded study of PMS patients (Chuong et al., 1988). 
We found no evidence of excessive slowing (ML study) or acceleration (LL study) of LH 
pulse frequency which might have been predicted if neuroendocrine regulatory mechanisms 
were dysfunctional. Given the degree of intragroup variability in LH pulse frequency, we were 
unable to detect small to modest differences in the regulation of GnRI-I secretion in the PMS 
patients. A true difference of this questionable magnitude seems an unlikely mediator of PMS 
symptomatology, however, and the pattern of pulsatile LH secretion in PMS patients was similar 
to that described in previous studies of normal volunteers (Santen & Bardin, 1973; Backstrom 
et  al., 1982; Filicori et  al., 1984; Reame et  al., 1984). Taken together, these results provide 
evidence that the symptoms of PMS can occur in the absence of marked abnormalities in the 
neuroreproductive axis and challenge the view that opioid inhibition of GnRH secretion is 
impaired. These findings, however, do not rule out aberrations in other steroid-mediated opioid 
action external to the hypothalamus that could play a role in the emotional and cognitive 
symptoms associated with this disorder. 
Further studies are necessary to confirm our finding of higher FSH secretion in PMS 
patients, but it would seem to suggest a lowered sensitivity of FSH to ovarian feedback regula- 
tion. Interestingly, this effect was most pronounced during the ML phase, a time when inhibin 
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is bel ieved to act in concert  with E 2 to inhibit  FSH secretion, and may  suggest  an area for future 
study. To what  extent  a dampening o f  the ovarian feedback regulat ion o f  FSH release might  be 
related to the cycl ic  psychologic  and behavioral  disturbances of  PMS is pure ly  speculat ive at 
present. 
P secretion, when measured  every 30 min in the ML phase,  was observed to be pulsati le in 
PMS patients and s imilar  to that reported for normal  women (Fil icori  et al., 1984). This finding 
further strengthens evidence from studies of  dai ly  hormone measures  that the abil i ty to secrete 
ovulatory levels of  ovarian steroids is not compromised  in PMS (Rubinow et al., 1988). More 
over, our  finding that per ipheral  p lasma P concentrations bear  no relat ionship to PMS symptom 
severity fails to support  the use of  ovarian steroids in the treatment of  this disorder. 
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